Bone involvement in primary cutaneous diffuse large B-cell lymphoma, leg-type.


Journal

Clinical and experimental dermatology
ISSN: 1365-2230
Titre abrégé: Clin Exp Dermatol
Pays: England
ID NLM: 7606847

Informations de publication

Date de publication:
02 Feb 2023
Historique:
received: 04 07 2022
revised: 05 10 2022
entrez: 2 2 2023
pubmed: 3 2 2023
medline: 7 2 2023
Statut: ppublish

Résumé

Primary cutaneous diffuse large B-cell lymphoma, leg-type (PCDLBCL-LT) is an aggressive cutaneous lymphoma. Bone involvement is rare and poorly described. We present five cases of PCDLBCL-LT with bone localization. In four cases, the bone involvement was diagnosed during the initial staging with positron emission tomography (PET) or computed tomography (CT) scan, and in the fifth case after tibial fracture during treatment with rituximab (RTX) and polychemotherapy (PCT). PCDLBCL-LT can be asymptomatic and involve bone sites distant from cutaneous lesions. None had other extracutaneous involvement. In our series, all patients received RTX-PCT as first-line chemotherapy and all had early relapses or progression. Second-line treatments had poor efficacy. Our series shows that bone involvement seems to be associated with poor prognosis in PCDLBCL-LT. Bone localization is not diagnosed with initial thoracic-abdominal-pelvic CT when asymptomatic and affecting the limbs only. If there is a suspicion of PCDLBCL-LT, patients should undergo systematic investigation with alternative imaging techniques, including PET, both at baseline and if there is any concern during follow-up.

Identifiants

pubmed: 36730524
pii: 6831430
doi: 10.1093/ced/llac044
doi:

Substances chimiques

Rituximab 4F4X42SYQ6

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

116-120

Informations de copyright

© The Author(s) 2022. Published by Oxford University Press on behalf of British Association of Dermatologists. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Déclaration de conflit d'intérêts

Conflict of interest The authors declare that they have no conflict of interest.

Auteurs

Claire Laurent (C)

Department of Dermatology, University Hospital of Rennes, Rennes, France.

Caroline Ram-Wolff (C)

Department of Dermatology, Saint-Louis Hospital, Paris, France.
French Study Group on Cutaneous Lymphomas (GFELC).

Saskia Ingen-Housz-Oro (S)

French Study Group on Cutaneous Lymphomas (GFELC).
Department of Dermatology, AP-HP, Henri-Mondor Hospital, Créteil, France.

Marie Beylot-Barry (M)

French Study Group on Cutaneous Lymphomas (GFELC).
Department of Dermatology, University Hospital of Bordeaux, Bordeaux, France.

Stephane Barete (S)

French Study Group on Cutaneous Lymphomas (GFELC).
Department of Dermatology, Pitié-Salpetrière Hospital, Paris, France.

Clemence Saillard (C)

Department of Dermatology, University Hospital of Rennes, Rennes, France.

Alain Dupuy (A)

Department of Dermatology, University Hospital of Rennes, Rennes, France.

Martine Bagot (M)

Department of Dermatology, Saint-Louis Hospital, Paris, France.
French Study Group on Cutaneous Lymphomas (GFELC).

Henri Adamski (H)

Department of Dermatology, University Hospital of Rennes, Rennes, France.
French Study Group on Cutaneous Lymphomas (GFELC).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH